MA31225B1 - Anticorps neutralisants des cytomegalovirus humains et leur utilisation - Google Patents

Anticorps neutralisants des cytomegalovirus humains et leur utilisation

Info

Publication number
MA31225B1
MA31225B1 MA32141A MA32141A MA31225B1 MA 31225 B1 MA31225 B1 MA 31225B1 MA 32141 A MA32141 A MA 32141A MA 32141 A MA32141 A MA 32141A MA 31225 B1 MA31225 B1 MA 31225B1
Authority
MA
Morocco
Prior art keywords
antibodies
cytomegalovirus
tie
human antibody
well
Prior art date
Application number
MA32141A
Other languages
Arabic (ar)
English (en)
Inventor
Antonio Lanzavecchia
Annalisa Macagno
Original Assignee
Humabs Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37801734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31225(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Humabs Llc filed Critical Humabs Llc
Publication of MA31225B1 publication Critical patent/MA31225B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/089—Cytomegalovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur des anticorps neutralisants qui sont spécifiques au cytomégalovirus humain et qui se lient avec une affinité élevée, ainsi que sur des lymphocytes b immortalisés qui produisent de tels anticorps. Les anticorps de l'invention ont également une activité thérapeutique élevée pour la neutralisation d'infections. L'invention porte également sur les épitopes auxquels les anticorps se lient, ainsi que sur l'utilisation des anticorps et des épitopes dans des procédés de criblage de même que dans le diagnostic et la thérapie de maladies.
MA32141A 2007-01-04 2009-08-04 Anticorps neutralisants des cytomegalovirus humains et leur utilisation MA31225B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0700133.2A GB0700133D0 (en) 2007-01-04 2007-01-04 Human cytomegalovirus neutralising antibodies and use thereof
PCT/IB2008/001111 WO2008084410A2 (fr) 2007-01-04 2008-01-03 Anticorps neutralisants des cytomégalovirus humains et leur utilisation

Publications (1)

Publication Number Publication Date
MA31225B1 true MA31225B1 (fr) 2010-03-01

Family

ID=37801734

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32141A MA31225B1 (fr) 2007-01-04 2009-08-04 Anticorps neutralisants des cytomegalovirus humains et leur utilisation

Country Status (31)

Country Link
US (4) US7955599B2 (fr)
EP (3) EP2487187B1 (fr)
JP (2) JP5710123B2 (fr)
KR (2) KR101659306B1 (fr)
CN (1) CN101657467B (fr)
AU (1) AU2008204258B2 (fr)
BR (1) BRPI0806185A2 (fr)
CA (1) CA2673755C (fr)
CO (1) CO6220862A2 (fr)
CR (1) CR10961A (fr)
CY (1) CY1114271T1 (fr)
DK (1) DK2118140T3 (fr)
EC (1) ECSP099547A (fr)
ES (2) ES2426987T3 (fr)
GB (1) GB0700133D0 (fr)
GT (1) GT200900188A (fr)
HR (1) HRP20130877T1 (fr)
IL (1) IL199585A (fr)
MA (1) MA31225B1 (fr)
MX (1) MX2009007320A (fr)
MY (2) MY150709A (fr)
NZ (1) NZ578844A (fr)
PL (1) PL2118140T3 (fr)
PT (2) PT2487187E (fr)
RU (1) RU2469045C2 (fr)
SG (3) SG191635A1 (fr)
SI (1) SI2118140T1 (fr)
TN (1) TN2009000285A1 (fr)
UA (1) UA100682C2 (fr)
WO (1) WO2008084410A2 (fr)
ZA (1) ZA200905408B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654563A1 (fr) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Complexe de proteine de surface du cytomegalovirus destine a etre utilise dans des vaccins et en tant que cible de medicament
GB0700133D0 (en) * 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
WO2009021150A2 (fr) * 2007-08-08 2009-02-12 California Pacific Medical Center Le récepteur du facteur de croissance dérivés des plaquettes tolère l'infectiosité du cytomégalovirus
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
KR101407216B1 (ko) * 2008-07-16 2014-06-16 인스티튜트 포 리서치 인 바이오메드슨 인간 사이토메갈바이러스 중화 항체 및 이의 용도
AU2012203417B2 (en) * 2008-07-16 2014-07-10 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
CA2733218A1 (fr) 2008-07-25 2010-01-28 Institute For Research In Biomedicine Anticorps neutralisant anti-virus influenza a et leurs utilisations
ES2539751T3 (es) 2009-04-01 2015-07-03 Evec Incorporated Anticuerpo monoclonal capaz de unirse con epítopo discontinuo específico que aparece en la región AD1 de la glucoproteína gB de citomegalovirus humano, y fragmento de unión a antígeno del mismo
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
CN103221063B (zh) 2010-06-16 2016-08-24 特瑞利斯生物科学有限责任公司 针对人类巨细胞病毒(cmv)gb蛋白质的高亲和力人类抗体
EP3418300B1 (fr) 2011-07-18 2020-10-28 Institute for Research in Biomedicine Anticorps neutralisant le virus de la grippe a et leurs utilisations
WO2013148373A1 (fr) 2012-03-28 2013-10-03 Genentech, Inc. Anticorps idiotypiques anti-hcmv et leurs utilisations
WO2014099908A1 (fr) * 2012-12-17 2014-06-26 Genentech, Inc. Méthodes d'inhibition de l'infection virale chez les patient greffés
PT3052192T (pt) 2013-10-02 2020-09-24 Medimmune Llc Anticorpos neutralizantes anti-influenza a e suas utilizações
CA2954780A1 (fr) 2014-07-15 2016-01-21 Medimmune, Llc Neutralisation d'anticorps anti-grippe b et leurs utilisations
US20160069643A1 (en) * 2014-09-06 2016-03-10 Philip Lyren Weapon Targeting System
EP3960761A1 (fr) 2015-06-01 2022-03-02 MedImmune, LLC Molécules de liaison anti-grippales neutralisantes et utilisations correspondantes
CA3010223A1 (fr) * 2016-01-08 2017-07-13 Aimm Therapeutics B.V. Composes de liaison therapeutiques
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
CA3019588A1 (fr) 2016-04-20 2017-10-26 Merck Sharp & Dohme Corp. Proteines de liaison a un antigene de neutralisation des cmv
US12037382B2 (en) * 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
CN109580944A (zh) * 2018-12-07 2019-04-05 潍坊医学院 一种人巨细胞病毒检测试纸及其制造方法
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
CN109738631A (zh) * 2019-01-21 2019-05-10 潍坊医学院 一种人巨细胞病毒IgM抗体检测试纸的制备方法
CN112898414B (zh) * 2019-12-04 2024-05-10 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide
CN118580343B (zh) * 2022-10-21 2025-08-19 珠海泰诺麦博制药股份有限公司 抗人巨细胞病毒抗体及其用途

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1061943A (en) 1964-09-10 1967-03-15 Carter S Ink Co Marking composition
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3766162A (en) 1971-08-24 1973-10-16 Hoffmann La Roche Barbituric acid antigens and antibodies specific therefor
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4294817A (en) 1977-11-25 1981-10-13 International Diagnostic Technology, Inc. Method of fluoro immunoassay
US4233402A (en) 1978-04-05 1980-11-11 Syva Company Reagents and method employing channeling
US4313927A (en) 1979-10-19 1982-02-02 Ames-Yissum Ltd. Immunoassay method for detecting viral antibodies in whole blood samples
US4334016A (en) 1980-06-19 1982-06-08 The Wistar Institute Of Anatomy And Biology Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
FR2543570B1 (fr) 1983-03-31 1985-08-09 Pasteur Institut Anticorps monoclonaux anticytomegalovirus humains, hybridomes secreteurs de ces anticorps et polypeptides porteurs d'un determinant antigenique sequentiel de cytomegalovirus humains
US4617379A (en) 1983-06-14 1986-10-14 Miles Laboratories, Inc. High titer cytomegalovirus immune serum globulin
GB8404368D0 (en) 1984-02-20 1984-03-28 Cogent Ltd Monoclonal antibodies to human cytomegalovirus
US6100064A (en) 1984-04-06 2000-08-08 Chiron Corporation Secreted viral proteins useful for vaccines and diagnostics
FR2563630B1 (fr) 1984-04-27 1988-02-19 Pasteur Institut Anticorps monoclonaux anticytomegalovirus et procedes pour le diagnostic in vitro des infections par les cytomegalovirus humains et d'une proteine-kinase inductible par les cytomegalovirus et susceptible d'etre reconnue par les susdits anticorps monoclonaux
US4783399A (en) 1984-05-04 1988-11-08 Scripps Clinic And Research Foundation Diagnostic system for the detection of cytomegalovirus
US4743562A (en) 1984-08-21 1988-05-10 The Board Of Trustees Of The Leland Stanford Junior University Purified human cytomegalovirus protein
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
WO1986002092A1 (fr) 1984-09-28 1986-04-10 Teijin Limited Hybridome homme-souris produisant un anticorps humain antiviral, procede de preparation et anticorps monoclonal humain antiviral
US4808518A (en) 1985-02-11 1989-02-28 University Of Tennessee Research Corporation Recovery of cytomegalovirus antigen and use thereof in an assay
US4804627A (en) 1985-05-09 1989-02-14 Sloan-Kettering Institute For Cancer Research Method for cloning lymphoblastoid cells
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1987003602A1 (fr) * 1985-12-06 1987-06-18 Teijin Limited Anticorps monoclonal humain contre le virus megalocytique et procede de preparation dudit anticorps
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5153311A (en) 1986-11-24 1992-10-06 The Children's Hospital, Incorporated Immunogenic glycoproteins of human cytomegalovirus gCII
US5126130A (en) 1986-11-24 1992-06-30 The Childrens Hospital Incorporated Monoclonal antibodies reactive with specific antigenic sites on human cytomegalovirus glycoprotein a
LU86752A1 (fr) 1987-01-30 1988-08-23 Univ Bruxelles Procede de production d'anticorps monoclonaux humains(igg)anticytomegalovirus et anticorps monoclonaux ainsi obtenus
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5180813A (en) 1989-03-24 1993-01-19 University Of Iowa Research Foundation Early envelope glycoprotein of human cytomegalovirus (hmcv) and monoclonal antibodies to the glycoproteins
US5194654A (en) 1989-11-22 1993-03-16 Vical, Inc. Lipid derivatives of phosphonoacids for liposomal incorporation and method of use
WO1991004277A1 (fr) 1989-09-14 1991-04-04 Children's Biomedical Research Institute Anticorps monoclonaux specifiques contre une glycoproteine de cytomegalovirus
WO1991005876A1 (fr) 1989-10-20 1991-05-02 Children's Biomedical Research Institute Cocktail d'anticorps monoclonaux specifiques du cytomegalovirus humain
GB9008223D0 (en) 1990-04-11 1990-06-13 Royal Free Hosp School Med Improvements relating to the detection of viruses
DE4035174A1 (de) 1990-11-06 1992-05-07 Biotest Ag Verfahren zur bestimmung von proteinen in koerperfluessigkeiten und mittel zur durchfuehrung des verfahrens
US5997878A (en) 1991-03-07 1999-12-07 Connaught Laboratories Recombinant poxvirus-cytomegalovirus, compositions and uses
JPH053794A (ja) * 1991-06-26 1993-01-14 Green Cross Corp:The 抗サイトメガロウイルスヒトモノクローナル抗体およびその産生細胞
DE4128684A1 (de) 1991-08-29 1993-03-04 Behringwerke Ag Hcmv-spezifische peptide, mittel dazu und ihre verwendung
ES2125248T3 (es) 1992-04-10 1999-03-01 Thomas Totterman Metodo de deteccion de una infeccion cmv.
SE9201281L (sv) 1992-04-23 1993-10-24 Bioinvent Int Ab Nya humana monoklonala antikroppar och förfarande för framställning därav
JPH05260961A (ja) * 1992-05-21 1993-10-12 Teijin Ltd サイトメガロウイルスに対するヒト・モノクローナル抗体を産生するハイブリドーマ
GB9221654D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant human anti-cytomegalovirus antibodies
ATE179613T1 (de) 1993-01-21 1999-05-15 Erna Moeller Verhütung und behandlung von zytomegalovirus mittels aminopeptidase
AU695584B2 (en) 1993-01-28 1998-08-20 Novartis Pharmaceutical Corporation Human monoclonal antibodies to cytomegalovirus
US5750106A (en) 1993-01-28 1998-05-12 Novartis Ag Human monoclonal antibodies to cytomegalovirus
AU6777594A (en) 1993-04-30 1994-11-21 Scripps Research Institute, The Human monoclonal antibodies to human cytomegalovirus, and methods therefor
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
EP0702083A3 (fr) 1994-07-26 1997-01-15 Biotest Ag Polypeptides et protéines fusionnées contenant la structure à lecture ouverte UL57 ou la séquence C-terminal de la protéine pp150 de tégument de HCMV, oligonucléotides et trousses diagnostiques correspondantes
US5783383A (en) 1995-05-23 1998-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of detecting cytomegalovirus (CMV)
US6019980A (en) 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US5800981A (en) 1996-02-22 1998-09-01 University Of Limburg Human cytomegalovirus antigen and its use
AU735981B2 (en) 1996-07-12 2001-07-19 Akzo Nobel N.V. Peptide reagent for the detection of human cytomegalovirus (CMV)
US6291437B1 (en) 1996-08-14 2001-09-18 The Wistar Institute Of Anatomy And Biology Methods and compositions for retarding the development of atherosclerotic lesions
WO1998033892A1 (fr) 1997-01-30 1998-08-06 Cedars-Sinai Medical Center Creation d'une lignee cellulaire lymphomateuse a hsv-8+, virus produit, anticorps, methode diagnostique et trousse pour detecter l'infection par le hsv-8
US6183752B1 (en) 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6300104B1 (en) 1997-06-19 2001-10-09 The Regents Of The University Of California Secretory immunoglobulin produced by single cells and methods for making and using same
JP2001512662A (ja) 1997-07-18 2001-08-28 コノート ラボラトリーズ リミテッド 呼吸器合胞体ウイルスのｇタンパク質をコードする核酸ワクチン
CA2309826A1 (fr) 1997-11-14 1999-05-27 Connaught Laboratories Limited Vecteurs d'alphavirus pour les vaccins de paramyxovirus
DE19756214C1 (de) 1997-12-17 1999-02-25 Biotest Ag Polypeptide mit Aminosäuresequenzen aus dem N-terminalen Bereich von gp116 und deren Verwendung bei der Diagnostik, Prophylaxe und Therapie
WO1999045952A2 (fr) 1998-03-12 1999-09-16 Genentech, Inc. Methode de prevention de la mort des neurones de la retine et de traitement d'affections oculaires
JP2002519334A (ja) 1998-06-29 2002-07-02 ベルクター，ヴォルフガンク αエミッタとβエミッタとを主成分とする抗ウイルスおよび抗レトロウイルス放射免疫薬剤
RU2133472C1 (ru) 1998-09-16 1999-07-20 Унитарное государственное Московское предприятие по производству бактерийных препаратов Способ диагностики активной стадии цитомегаловирусной инфекции человека
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US20020102208A1 (en) 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
ITMI20012160A1 (it) 2001-10-18 2003-04-18 Edoardo Marchisio Sistema immunoenzimatico per la caratterizzazione antigenica dell'infezione attiva da cytomegalovirus e cmv confirmation test
US6828113B2 (en) 2002-03-21 2004-12-07 Cornell Research Foundation, Inc. IgM antibodies to the 70 kDa heat shock protein as a marker for cytomegalovirus infection
EP1578980A4 (fr) 2002-04-01 2013-01-02 Agensys Inc Acide nucleique et proteine correspondante 213p1f11 que l'on utilise dans le traitement et la detection du cancer
RU2239453C2 (ru) * 2002-12-03 2004-11-10 Федеральное государственное унитарное предприятие " Научно-производственное объединение по медицинским иммунобиологическим препаратам " Микроген" Препарат иммуноглобулина человека против цитомегаловируса и способ его получения
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
US20040228842A1 (en) 2003-02-27 2004-11-18 Shan Lu Compositions and methods for cytomegalovirus treatment
US20060216302A1 (en) 2003-02-28 2006-09-28 Robert Root-Bernstein Immunological markers
KR20150041193A (ko) 2004-06-21 2015-04-15 메다렉스, 엘.엘.시. 인터페론 알파 수용체 1 항체 및 그의 용도
BE1016287A6 (nl) 2004-07-14 2006-07-04 Picanol Nv Gaapvormingsonderdeel voor een weefmachine en weefmachine.
WO2006056027A1 (fr) 2004-11-29 2006-06-01 The Council Of The Queensland Institute Of Medical Research Immunotherapie contre le cytomegalovirus humain
DE602005027258D1 (de) 2005-03-14 2011-05-12 Us Gov Health & Human Serv Humane monoklonale antikörper gegen hendra- und nipah-viren
PL1974020T3 (pl) 2005-12-16 2011-11-30 Ribovax Biotechnologies Sa Sposoby uzyskiwania unieśmiertelnionych komórek wydzielających przeciwciała
WO2007094423A1 (fr) 2006-02-15 2007-08-23 Evec Incorporated Anticorps monoclonal humain capable de se lier au cytomegalovirus humain et domaine de liaison antigene de l'anticorps
ZA200810677B (en) 2006-05-19 2010-03-31 Teva Pharma Fusion proteins, uses thereof and processes for producing same
CA2654563A1 (fr) 2006-06-07 2007-12-21 The Trustees Of Princeton University Complexe de proteine de surface du cytomegalovirus destine a etre utilise dans des vaccins et en tant que cible de medicament
ATE503769T1 (de) 2006-12-15 2011-04-15 Ribovax Biotechnologies Sa Antikörper gegen das humane cytomegalie-virus (hcmv)
US7947274B2 (en) 2007-01-04 2011-05-24 Humabs, LLC. Human cytomegalovirus neutralising antibodies and use thereof
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
WO2008120203A2 (fr) 2007-03-29 2008-10-09 Technion Research & Development Foundation Ltd. Procédés de diagnostic et de traitement de maladies provoquées par le cytomégalovirus
US20080248042A1 (en) 2007-04-05 2008-10-09 Irccs Centro Di Riferimento Oncologico Di Aviano, Monoclonal antibody cross-reactive against infective agent causing a B-cell expansion and IgG-Fc
EP2190876A1 (fr) 2007-08-22 2010-06-02 Ribovax Biotechnologies SA Anticorps dirigés contre le cytomégalovirus humain (hcmv)
US7763261B2 (en) 2007-12-19 2010-07-27 Dcb-Usa Llc Anti-human cytomegalovirus antibodies
KR101407216B1 (ko) 2008-07-16 2014-06-16 인스티튜트 포 리서치 인 바이오메드슨 인간 사이토메갈바이러스 중화 항체 및 이의 용도
PT3009449T (pt) * 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes

Also Published As

Publication number Publication date
WO2008084410A3 (fr) 2008-12-24
EP2860189A3 (fr) 2015-07-29
IL199585A (en) 2014-07-31
US8545848B2 (en) 2013-10-01
ES2426987T3 (es) 2013-10-28
ZA200905408B (en) 2010-05-26
JP2010516229A (ja) 2010-05-20
SG177943A1 (en) 2012-02-28
SG192399A1 (en) 2013-08-30
GT200900188A (es) 2011-11-29
US9149524B2 (en) 2015-10-06
MX2009007320A (es) 2010-02-22
KR101541927B1 (ko) 2015-08-05
UA100682C2 (ru) 2013-01-25
CY1114271T1 (el) 2016-08-31
HK1139158A1 (en) 2010-09-10
NZ578844A (en) 2012-08-31
PL2118140T3 (pl) 2013-11-29
KR20140101884A (ko) 2014-08-20
EP2487187B1 (fr) 2014-10-22
US20130101604A1 (en) 2013-04-25
US8309089B2 (en) 2012-11-13
CN101657467B (zh) 2013-11-06
PT2487187E (pt) 2015-02-05
JP5710123B2 (ja) 2015-04-30
AU2008204258A1 (en) 2008-07-17
EP2118140B1 (fr) 2013-06-19
US7955599B2 (en) 2011-06-07
HRP20130877T1 (hr) 2013-10-25
KR101659306B1 (ko) 2016-09-23
CO6220862A2 (es) 2010-11-19
BRPI0806185A2 (pt) 2011-08-30
RU2009129403A (ru) 2011-02-10
CA2673755C (fr) 2016-04-05
MY150709A (en) 2014-02-28
AU2008204258B2 (en) 2012-09-06
HK1174344A1 (en) 2013-06-07
SI2118140T1 (sl) 2013-10-30
CR10961A (es) 2009-11-20
MY161200A (en) 2017-04-14
US20120076802A1 (en) 2012-03-29
DK2118140T3 (da) 2013-07-01
CA2673755A1 (fr) 2008-07-17
PT2118140E (pt) 2013-08-29
WO2008084410A2 (fr) 2008-07-17
SG191635A1 (en) 2013-07-31
EP2118140A2 (fr) 2009-11-18
KR20090127256A (ko) 2009-12-10
EP2487187A3 (fr) 2012-11-21
JP2014141501A (ja) 2014-08-07
EP2860189A2 (fr) 2015-04-15
TN2009000285A1 (en) 2010-12-31
ECSP099547A (es) 2009-11-30
GB0700133D0 (en) 2007-02-14
CN101657467A (zh) 2010-02-24
US20080213265A1 (en) 2008-09-04
US20140056914A1 (en) 2014-02-27
EP2487187A2 (fr) 2012-08-15
RU2469045C2 (ru) 2012-12-10
ES2526907T3 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
MA32566B1 (fr) Anticorps neutralisant les cytomégalovirus humains et leurs utilisations
MA33402B1 (fr) Compositions et procédés de ciblage de la proteine c3b de complément par des anticorps
MA32725B1 (fr) Anticorps contre l'il 17 humaine et utilisations associees
UA109633C2 (uk) Антитіло людини проти тканинного фактора
MA28982B1 (fr) Anticorps antagonistes de il-17
PH12022551650A1 (en) Anti-trem2 antibodies and methods of use thereof
MA31991B1 (fr) Anticorps contre le virus de la grippe et procedes pour leur utilisation
WO2018056821A8 (fr) Molécules de liaison qui modulent une activité biologique exprimée par une cellule
MA37761A1 (fr) Protéines de liaison à un antigène antagoniste d'un double récepteur et leurs utilisations
EA200500441A1 (ru) Терапевтическое человеческое моноклональное антитело против il-1r1
MA30962B1 (fr) Anticorps antifacteurs d'humanisés et leurs utilisations.
MA40497A (fr) Anticorps et récepteurs antigéniques chimériques spécifiques du cd19
MA33534B1 (fr) Anticorps humains d'affinité élevée dirigés contre l'angiopoïétine 2 humaine
PH12021552002A1 (en) Anti-trem2 antibodies and methods of use thereof
WO2003106498A3 (fr) Molecules de liaison agonistes au recepteur ox40 humain
EP2143795A3 (fr) Anticorps monoclonal anti-CD20
MA35620B1 (fr) Compositions pour le traitement de l'arthrite rhumatoïde et procédés d'utilisation desdites compositions
WO2005012493A3 (fr) Anticorps anti-cd19
MA42530B1 (fr) Constructions d'anticorps bispécifiques se liant à dll3 et à cd3
MA33381B1 (fr) Proteine de liaison a il-13
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
EP2826791A3 (fr) Anticorps anti-C5aR humanisés
TNSN07401A1 (fr) Anticorps diriges contre le peptide amyloide-beta, et methodes pour leurs utilisations
MY182750A (en) Assays for detecting antibodies specific to therapeutic anti-ige antibodies and their use in anaphylaxis